Key result
CHD polygenic risk score linked to ~69% higher MACE risk per SD in T2D.
Why the study?
Current clinical risk prediction may misclassify individuals with type 2 diabetes as low cardiovascular risk and could be improved by adding a coronary heart disease polygenic risk score.
Does the addition of a CHD polygenic risk score to clinical risk assessment improve prediction of MACE in patients with type 2 diabetes without prior cardiovascular disease?
Population
10,556 individuals with type 2 diabetes aged 40-79 years without prior cardiovascular hospitalization
Comparison
CHD polygenic risk score plus clinical risk score vs clinical risk score alone
Design
Cohort study
Follow-up
10 years
Authors
Loading...
May refine MACE prediction in T2D without CVD; leaves open clinical utility pending prospective validation.
Cohort (n=10,556)
Does the addition of a CHD polygenic risk score to clinical risk assessment improve prediction of MACE in patients with type 2 diabetes without prior cardiovascular disease?
Hazard Ratio: 1.69 (95% CI 1.6–1.79)
The addition of a CHD polygenic risk score to standard clinical assessment significantly improves MACE prediction in patients with type 2 diabetes without prior cardiovascular disease, especially in those deemed low clinical risk.
Mordi et al. (2024) conducted a cohort in Type 2 diabetes (n=10,556). Coronary heart disease polygenic risk score (PRS) vs. Clinical risk score (Pooled Cohort Equation) / lower PRS quintiles was evaluated on Time to first major adverse cardiovascular event (MACE) (HR 1.69, 95% CI 1.60-1.79). A coronary heart disease polygenic risk score was significantly associated with incident MACE in patients with type 2 diabetes (HR 1.69 per SD increase; 95% CI 1.60-1.79).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: